Research reports improved outcomes with mineralocorticoid receptor antagonists across different types of heart failure
Mineralocorticoid receptor antagonists (MRAs) reduced the risk of cardiovascular death or heart failure (HF) hospitalization in patients with HF and reduced ejection fraction (HFrEF) and also in those with mildly reduced ...
Sep 5, 2024
0
0